Immunitybio announces execution of $40 million equity financing with institutional investors

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx), a clinical-stage immunotherapy company, today announced that it has executed financing to provide further working capital and support its ongoing business operations. the company entered into a securities purchase agreement for a registered direct offering with multiple institutional investors, providing for the issuance of common stock of immunitybio as well as warrants for the purchase of additional shares of common stock.
IBRX Ratings Summary
IBRX Quant Ranking